Tag: Novartis

Pharmaceutical Industry Advances Digital CMC and Manufacturing Efficiency

Leading pharmaceutical and technology companies have launched the Digital CMC Consortium to modernize drug development and manufacturing. The initiative aims to remove information bottlenecks through standardized digital workflows and interoperable systems.The not-for-profit consortium includes Novartis, Thermo Fisher Scientific, Takeda, Rockwell Automation, Flagship’s Pioneering Medicines, Stellix, ZS Associates, and QbDVision. Together, these organizations will develop practical digital solutions for Chemistry, Manufacturing and Controls (CMC).CMC covers the processes used to develop, manufacture, test, and control pharmaceutical products. However, many companies still rely on manual documentation, disconnected software, and inconsistent data formats. These limitations can slow technology transfer and complicate coordination across global manufacturing networks.The Consortium aims to address these challenges through shared data standards, reusable digital models, and interoperable infrastructure. Consequently, pharmaceutical companies can improve information exchange and reduce repetitive documentation throughout drug development.

Novartis and Industry Partners Promote Digital Standards

The Digital CMC Consortium follows a pre-competitive collaboration model. Members can address common technical challenges together without independently developing overlapping solutions.The initiative integrates existing industry guidelines and identifies areas that require additional standards. Moreover, members are developing software tools and code that help companies implement these standards in practical workflows.Achim Frauenschuh, Co-Chair of the Digital CMC Consortium and Associate Director of Science and Technology Drug Substance Development at Novartis, highlighted the value of shared digital foundations.He emphasized that collaborative investment gives members access to structured data models, standardized templates, and implementation guidance. These resources can reduce duplicated engineering effort and help companies apply digital standards more consistently.For industrial automation teams, this approach reflects a broader trend toward interoperability across control systems, manufacturing software, and enterprise applications. Standardized information structures can also support more consistent communication between production facilities and pharmaceutical technology platforms.

Digital Technology Transfer Becomes a Key CMC Priority

After its first year of collaboration and proof-of-concept activities, the Consortium is preparing to expand practical industry adoption. Its initial priority focuses on technology transfer between pharmaceutical companies and contract development and manufacturing organizations (CDMOs).Technology transfer requires teams to exchange process knowledge, manufacturing instructions, analytical methods, and quality information. However, document-heavy workflows can create inconsistencies when companies move processes between development laboratories and commercial production sites.The Consortium aims to replace fragmented documentation with structured, reusable digital information. This approach could simplify information handovers, improve consistency, and support collaboration across manufacturing partners.Mike Stapleton, Chairman of the Digital CMC Consortium and Chief Business Officer at QbDVision, highlighted the opportunity to extend digital transformation beyond drug discovery and clinical trials. He identified CMC as another major area where connected digital workflows can improve pharmaceutical operations.As global supply chains become more complex, companies need systems that exchange technical information accurately. Therefore, interoperability will remain important when connecting manufacturing sites, digital platforms, and regulatory processes.

Industrial Automation Supports Connected Pharmaceutical Manufacturing

Digital CMC initiatives also have implications for industrial automation and pharmaceutical production systems. Modern facilities use PLC controllers, distributed control systems (DCS), industrial networks, and manufacturing execution systems to manage production activities.These technologies generate operational data that supports process monitoring, equipment control, batch execution, and quality management. However, companies gain greater value when they connect operational data with structured product and process information.For example, standardized data models can help align manufacturing parameters, process instructions, and quality records across different production environments. In addition, consistent information structures can support data exchange between plant-level control systems and higher-level manufacturing applications.The Consortium's stated focus is digital CMC rather than the development of PLC or DCS hardware. Nevertheless, its interoperability goals align with wider industrial automation efforts to reduce isolated data environments and improve manufacturing information management.

AI and Digital Twins Extend the Digital CMC Roadmap

The Consortium's longer-term roadmap includes knowledge management, automated content creation, digital twins, and artificial intelligence. These capabilities could help pharmaceutical companies reuse technical knowledge across multiple development and manufacturing stages.Digital twins can represent manufacturing processes or systems using data and computational models. When supported by suitable process information, they can help teams evaluate operating conditions and investigate process behavior.AI may also assist with technical documentation, information retrieval, and structured knowledge reuse. However, pharmaceutical organizations must evaluate these applications against data quality, validation, traceability, and applicable regulatory requirements.A connected digital CMC environment could reduce information silos between research, process development, manufacturing, and quality teams. As a result, companies may gain a clearer view of process knowledge throughout the product lifecycle.

Regulatory Alignment and Interoperability Shape Future Development

The Digital CMC Consortium also plans to provide a coordinated industry perspective when engaging with health authorities. Its objective is to support standards that serve internal operations and regulatory submissions.Consistent digital information can help companies manage technical documentation across development and manufacturing activities. Moreover, common standards can reduce the need to maintain separate information structures for different partners and workflows.Successful implementation will depend on industry participation, practical technical guidance, and alignment with regulatory expectations. Companies must also ensure that digital workflows preserve data integrity and provide appropriate oversight.

What the Digital CMC Consortium Means for Industrial Automation

The Consortium highlights the growing importance of digital interoperability in pharmaceutical manufacturing. Although its primary mission focuses on CMC processes, its objectives intersect with broader factory automation and manufacturing digitalization trends.PLC and DCS platforms will continue to manage equipment and process operations. Meanwhile, connected data architectures can help make production information more accessible to manufacturing, engineering, and quality teams.For pharmaceutical manufacturers, the next step involves connecting digital standards with practical operational workflows. If industry partners adopt these approaches consistently, they could improve technology transfer, reduce duplicated work, and support more connected drug development.The Consortium's progress will depend on how effectively its members translate shared standards into deployable solutions. Its work also reflects a wider industry shift toward interoperable manufacturing data, digital twins, and AI-enabled process knowledge management.